BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Jun 15, 2026; 18(6): 119114
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.119114
Table 3 Integrative landscape of molecular subtypes and immune phenotypes
Molecular subtype
Spatial phenotype
Key genomic drivers
Dominant immune mechanism
Recommended strategy
Epstein-Barr virus+Inflamed (hot)9p24.1 amp, PIK3CA mutViral pathogen-associated molecular patterns; constitutive programmed death-ligand 1Programmed cell death protein 1 monotherapy
Microsatellite instabilityInflamed (hot)Deficient mismatch repair, high tumor mutational burdenNeoantigen-driven recruitmentDual checkpoint blockade
Genomically stableExcluded (cold)CDH1/RHOA mut, CLDN18.2TGF-β fibrosis; myofibroblastic cancer-associated fibroblasts barriersAnti-CLDN18.2/TGF-β inhibitors
Chromosomal instabilityDesert/variableTP53 mut, receptor tyrosine kinase amp, somatic copy number alterationsHuman leukocyte antigen loss of heterozygosity; myeloid-driven suppressionTargeted + immune checkpoint inhibitors (e.g., human epidermal growth factor receptor 2-directed)


Write to the Help Desk